Everett Harris & Co. CA Has $3.19 Million Stock Holdings in Baxter International Inc. $BAX

Everett Harris & Co. CA trimmed its holdings in shares of Baxter International Inc. (NYSE:BAX) by 66.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 166,896 shares of the medical instruments supplier’s stock after selling 332,637 shares during the period. Everett Harris & Co. CA’s holdings in Baxter International were worth $3,189,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BAX. Dodge & Cox grew its position in shares of Baxter International by 10.1% in the 3rd quarter. Dodge & Cox now owns 57,396,370 shares of the medical instruments supplier’s stock valued at $1,306,915,000 after acquiring an additional 5,274,750 shares during the period. Greenhaven Associates Inc. grew its position in shares of Baxter International by 70.0% in the 4th quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier’s stock valued at $204,347,000 after acquiring an additional 4,404,874 shares during the period. SG Americas Securities LLC grew its position in shares of Baxter International by 477.6% in the 4th quarter. SG Americas Securities LLC now owns 1,725,251 shares of the medical instruments supplier’s stock valued at $32,970,000 after acquiring an additional 1,426,547 shares during the period. Geode Capital Management LLC grew its position in shares of Baxter International by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock valued at $257,174,000 after acquiring an additional 972,891 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of Baxter International by 32.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,515,928 shares of the medical instruments supplier’s stock valued at $57,243,000 after acquiring an additional 615,100 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Stock Performance

Shares of BAX stock opened at $19.24 on Tuesday. The company has a market capitalization of $9.94 billion, a price-to-earnings ratio of -9.03, a PEG ratio of 3.12 and a beta of 0.64. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.23 and a current ratio of 1.85. The company has a 50-day simple moving average of $17.93 and a 200 day simple moving average of $18.80. Baxter International Inc. has a 52 week low of $15.73 and a 52 week high of $32.04.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The business had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.62 billion. During the same quarter in the previous year, the company earned $0.62 EPS. The business’s revenue was up 2.9% on a year-over-year basis. On average, sell-side analysts predict that Baxter International Inc. will post 1.92 earnings per share for the current year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Friday, May 29th will be paid a $0.01 dividend. The ex-dividend date is Friday, May 29th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s payout ratio is -1.88%.

Analysts Set New Price Targets

A number of brokerages have recently commented on BAX. The Goldman Sachs Group lifted their price objective on shares of Baxter International from $17.00 to $19.00 in a research report on Friday, May 1st. Zacks Research raised shares of Baxter International from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Stifel Nicolaus decreased their price objective on shares of Baxter International from $20.00 to $19.00 in a research report on Friday, May 1st. Barclays lifted their price objective on shares of Baxter International from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Finally, Evercore decreased their price objective on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Baxter International has an average rating of “Reduce” and a consensus target price of $19.73.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.